This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis
Signal Transduction and Targeted Therapy Open Access 21 April 2023
-
Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model
Cancer & Metabolism Open Access 10 August 2020
-
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
Scientific Reports Open Access 06 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Cancer anabolic metabolism inhibitors move into clinic. Nat Biotechnol 34, 794–795 (2016). https://doi.org/10.1038/nbt0816-794
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0816-794
This article is cited by
-
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis
Signal Transduction and Targeted Therapy (2023)
-
Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model
Cancer & Metabolism (2020)
-
Tumour metabolism and its unique properties in prostate adenocarcinoma
Nature Reviews Urology (2020)
-
Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism
Nature Metabolism (2020)
-
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
Scientific Reports (2017)